Testi AM, Pession A, Diverio D, et al. Risk-adapted treatment of acute promyelocytic leukemia: results from the International Consortium for Childhood APL. Blood . 2018;132(4):405-412.

In the visual abstract, for high-risk (HR) patients in the ICC-APL-01 trial, the information for consolidation course 3 should read "ATRA + IDA + ARA-C," not "ATRA + IDA."The corrected visual abstract is shown below.Risk-adapted therapy for childhood APL: ICC-APL-01 vs GIMEMA/AIEOP AIDA 2000 Induction Consolidation Maintenance Comparison SR: Cumulative anthracycline dose 355 mg/m 2 SR: Cumulative anthracycline dose 650 mg/m 2 HR: Cumulative anthracycline dose 405 mg/m 2 HR: Cumulative anthracycline dose 650 mg/m 2